Mitral Regurgitation: The Leaking Valve and the Volume-Overloaded Ventricle

What Mitral Regurgitation Is and Why It Matters

The mitral valve is a bileaflet structure whose competence depends on an entire apparatus: the anterior and posterior leaflets, the fibrous annulus, the chordae tendineae, the papillary muscles, and the supporting left ventricular (LV) wall. Failure of any component causes regurgitation — retrograde flow from the LV into the left atrium (LA) during systole.

Clinically, MR is split into two fundamentally different diseases:

• Primary (organic/degenerative) MR — the leaflets/chordae themselves are diseased. The dominant cause in high-income countries is myxomatous degeneration (mitral valve prolapse), from florid Barlow disease in the young to fibroelastic deficiency in the elderly.
• Secondary (functional) MR — the valve is structurally normal but the ventricle or atrium is not; LV dilation displaces the papillary muscles and tethers the leaflets (ventricular functional MR), or a dilated LA in atrial fibrillation stretches the annulus (atrial functional MR).

It matters because chronic MR is a volume-overload lesion that silently remodels the ventricle. By the time symptoms appear, irreversible myocardial damage may already be underway.

The Pathophysiology, Step by Step

The hemodynamic sin of MR is a low-impedance leak into the LA. Because the LA is at far lower pressure than the aorta, blood preferentially escapes backward — this reduces LV afterload early in disease but at a steep long-term cost.

• Step 1 — Regurgitant volume. Each systole ejects blood both forward (effective stroke volume) and backward (regurgitant volume). The total volume the LV must handle rises.
• Step 2 — Volume overload. That regurgitant blood returns to the LV in diastole, increasing preload. The heart must now pump the same blood twice.
• Step 3 — Eccentric hypertrophy. Chronic volume overload triggers series addition of sarcomeres → the LV dilates with a proportional wall-thickness increase (eccentric remodeling). This normalizes wall stress by Laplace's law and preserves stroke volume for years — the compensated phase.
• Step 4 — Decompensation. Eventually the dilated LV develops contractile dysfunction; ejection fraction (EF) falls, LA pressure rises, and pulmonary congestion ensues. Because MR unloads the LV, a "normal" EF in MR actually reflects subnormal contractility — an EF below ~60% signals danger.

In acute MR, none of this compensation exists: a normal-sized, stiff LA cannot accommodate the volume, so LA and pulmonary venous pressures spike, causing flash pulmonary edema.

Clinical Presentation and Classic Signs

Chronic MR is notoriously insidious. Patients may be asymptomatic for decades, then present with exertional dyspnea, fatigue (low forward output), orthopnea, and palpitations once atrial fibrillation supervenes.

The hallmark physical finding is a blowing, high-pitched holosystolic (pansystolic) murmur best heard at the apex, radiating to the axilla (or to the back/base with posterior vs. anterior leaflet pathology):

• Timing: Holosystolic because LV pressure exceeds LA pressure throughout systole; the murmur may obscure S1.
• S3 gallop: Reflects rapid diastolic filling of the volume-overloaded LV (not necessarily failure in severe MR).
• Maneuvers: Louder with handgrip (↑ afterload ↑ regurgitation) and squatting; softer with Valsalva/standing.
• Mitral valve prolapse: A mid-systolic click followed by a late-systolic murmur; maneuvers that shrink the LV (standing, Valsalva) move the click earlier.

In acute severe MR, the classic murmur may be soft, short, or absent because LA and LV pressures equalize quickly — the patient instead crashes in pulmonary edema or shock, a dangerous mimic-masking pitfall.

Diagnosis — Tests, Criteria, and Cutoffs

Transthoracic echocardiography (TTE) is the cornerstone: it identifies the mechanism, quantifies severity, and tracks LV size/function. Transesophageal echo (TEE) gives superior leaflet detail for surgical planning; cardiac MRI is the reference standard when echo is discordant.

Severity of primary MR is graded by integrating multiple parameters — the accepted severe quantitative cutoffs are:

• Effective regurgitant orifice area (EROA) ≥ 0.40 cm² (by PISA / proximal isovelocity surface area)
• Regurgitant volume ≥ 60 mL/beat
• Regurgitant fraction ≥ 50%
• Supportive: vena contracta width ≥ 0.7 cm, holosystolic dense CW-Doppler jet, systolic flow reversal in the pulmonary veins

Additional workup:

• ECG: may show left atrial enlargement (broad, notched "P mitrale" in II), atrial fibrillation, or LVH.
• Chest X-ray: LA and LV enlargement; pulmonary congestion in acute/decompensated cases.
• Serial imaging tracks LV end-systolic diameter (LVESD) and EF — the triggers for intervention. BNP/NT-proBNP aids risk stratification.

Management at a Mechanism Level

There is no medical cure for primary MR — the leak is mechanical, so the definitive fix is mechanical. Timing hinges on avoiding irreversible LV damage.

• Mitral valve repair (preferred over replacement) restores leaflet coaptation and preserves the subvalvular apparatus, giving better long-term LV function and survival. Indicated in severe primary MR that is symptomatic, or asymptomatic with EF 30–60%, LVESD ≥ 40 mm, new atrial fibrillation, or pulmonary hypertension (systolic PA pressure > 50 mmHg).
• Transcatheter edge-to-edge repair (TEER / MitraClip) clips the leaflets to reduce the orifice — for high-surgical-risk primary MR and, per the COAPT trial, for select secondary MR on optimized therapy.
• Secondary (functional) MR is a ventricular disease: treat with guideline-directed medical therapy — ACE inhibitors/ARB/ARNI and beta-blockers reduce afterload and reverse-remodel the LV; MRAs and SGLT2 inhibitors add benefit; CRT resynchronizes and can shrink functional MR. Reducing LV size lifts leaflet tethering.
• Acute severe MR: afterload reduction (IV nitroprusside), diuretics, and an intra-aortic balloon pump stabilize while urgent surgery is arranged.

Distinguishing MR from Mimics and Do-Not-Miss Pitfalls

The holosystolic apical murmur has classic imitators that must be separated at the bedside and by echo:

• Tricuspid regurgitation: also holosystolic but heard at the left lower sternal border and increases with inspiration (Carvallo sign), unlike left-sided MR.
• Ventricular septal defect: harsh holosystolic murmur at the lower left sternal border with a palpable thrill; radiates across the precordium, not to the axilla.
• Aortic stenosis: a crescendo-decrescendo (not holosystolic) murmur that radiates to the carotids; MVP/MR can coexist and confuse.
• Hypertrophic obstructive cardiomyopathy: murmur increases with Valsalva/standing (opposite to MR).

Key pitfalls: (1) a preserved EF in severe MR is deceptive — an EF < 60% already indicates myocardial dysfunction; (2) in acute papillary muscle rupture after inferior MI, the murmur may be quiet while the patient is in shock — a missed surgical emergency; (3) in secondary MR, murmur loudness poorly reflects severity, so quantitative echo is mandatory; (4) new-onset atrial fibrillation in MR is both a symptom-equivalent and a trigger to intervene.

Acute vs. chronic and primary vs. secondary mitral regurgitation — mechanism, hemodynamics, and management

Feature	Acute severe MR	Chronic primary (degenerative) MR	Chronic secondary (functional) MR
Cause	Papillary muscle rupture (post-MI), chordal rupture, endocarditis	Myxomatous prolapse (Barlow, fibroelastic deficiency), rheumatic, calcific	LV dilation/dysfunction or LA dilation (AF) tethering an anatomically normal valve
LA/LV size	Normal size, non-compliant → sharp LA/pulmonary pressure rise	Dilated, compliant LA and eccentrically hypertrophied LV	Dilated LV (ischemic/dilated CMP); annular dilation
Presentation	Acute pulmonary edema, cardiogenic shock; murmur may be soft/absent	Often asymptomatic for years; DOE, fatigue, palpitations (AF)	Symptoms of underlying HF; murmur intensity poorly tracks severity
Severe echo cutoff	Qualitative — hemodynamic collapse dominates	EROA ≥0.40 cm², RVol ≥60 mL, RF ≥50%	EROA ≥0.40 cm² (some use ≥0.20 cm² as prognostically severe)
Definitive therapy	Emergent surgery (± IABP, afterload reduction as bridge)	Valve repair when severe + symptoms/EF 30–60%/ESD ≥40 mm/new AF/PHTN	GDMT + CRT first; TEER (MitraClip) if COAPT criteria met